Research perspective · 2 October 2026
NAD precursors and evidence for energy support
What a small combination-supplement trial can and cannot establish.
What the research found
A short crossover pilot tested a combined nicotinamide/D-ribose product and reported changes in NAD-related biomarkers. Fifty people were screened; the intention-to-treat population was 18 and the per-protocol population 17.
What it does not establish
A combination product does not isolate niacinamide. Biomarker changes do not establish treatment of insulin resistance, durable functional benefit or equivalence to DCA. Independent replication and longer follow-up are needed.
A research question for EPK
For EPK, the useful distinction is between nutrient adequacy and pharmacological supplementation. Trials should measure meaningful function and adverse effects, not assume higher blood NAD markers mean better whole-body energy availability.
Research and guidance
Explore more studies in the research library.
Related working papers
Read the relevant PDFs: EPK–001 to 007 are the revised version 1.2 papers; EPK–008 to 010 are version 1.0 supplements. Earlier PDFs and DOI records remain on the paper archive.